FDA Inspection 1170758 — Christopher E. Brightling, MBBS, PhD
The FDA completed an inspection of Christopher E. Brightling, MBBS, PhD on May 27, 2022 in Leicester. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 27, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Leicester (United Kingdom)
Additional Details
Clinical Investigator (CI)